Turn Therapeutics Inc.

NasdaqGM:TTRX Stock Report

Market Cap: US$271.7m

Turn Therapeutics Management

Management criteria checks 2/4

Turn Therapeutics' CEO is Bradley Burnam, appointed in Oct 2018, has a tenure of 7.75 years. total yearly compensation is $465.74K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 52.76% of the company’s shares, worth $143.33M. The average tenure of the management team and the board of directors is 1.2 years and 3.7 years respectively.

Key information

Bradley Burnam

Chief executive officer

US$465.7k

Total compensation

CEO salary percentage100.00%
CEO tenure7.8yrs
CEO ownership52.8%
Management average tenure1.2yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 15

Turn Therapeutics: Small Market Cap, Huge Potential

Summary Turn Therapeutics offers high risk-reward potential, hinging entirely on its late-stage asset GX-03 for Eczema and Onychomycosis. Recent Phase 2 data for GX-03 in moderate-to-severe AD and Onychomycosis show efficacy exceeding current topical competitors, with no reported adverse events. TTRX lacks sufficient capital to fund upcoming Phase 3 trials, requiring significant financing before Q3 2027, introducing dilution and operational risk. Given the current valuation and promising data, Turn merits close attention for investors interested in inflammatory skin disease, despite substantial clinical and financing risks. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Bradley Burnam's remuneration changed compared to Turn Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$4m

Dec 31 2025US$466kUS$466k

-US$3m

Sep 30 2025n/an/a

-US$4m

Jun 30 2025n/an/a

-US$3m

Mar 31 2025n/an/a

-US$2m

Dec 31 2024US$429kUS$429k

-US$2m

Sep 30 2024n/an/a

-US$2m

Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$429kUS$429k

-US$2m

Compensation vs Market: Bradley's total compensation ($USD465.74K) is below average for companies of similar size in the US market ($USD1.63M).

Compensation vs Earnings: Bradley's compensation has increased whilst the company is unprofitable.

CEO

Bradley Burnam (46 yo)

7.8yrs
Tenure
US$465,740
Compensation

Mr. Bradley E. Burnam is Founder of Turn Therapeutics, Inc. (Global Health Solutions, Inc.) and serves as its CEO and Director since October 2018. He is responsible for the development of Turn’s multiple F...

Leadership Team

NamePositionTenureCompensationOwnership
Bradley Burnam
Founder7.8yrsUS$465.74k52.76%
$ 143.3m
Zuraiz Chaudhary
Interim CFO1.2yrsUS$1.61m0.042%
$ 114.0k
Neilesh Ghodadra
Chief Medical Officer & Directorno dataUS$100.00k0%
$ 0
Mohammed Zubair
Controllerno datano datano data
Stephen Hahn
Executive Clinical & Regulatory Leadless than a yearno datano data
1.2yrs
Average Tenure
45.5yo
Average Age

Experienced Management: TTRX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Bradley Burnam
Founder7.8yrsUS$465.74k52.76%
$ 143.3m
Neilesh Ghodadra
Chief Medical Officer & Director7.8yrsUS$100.00k0%
$ 0
Arthur Golden
Independent Directorless than a yearUS$100.00k1.18%
$ 3.2m
Andrew Gengos
Independent Director6.5yrsUS$100.00k0%
$ 0
Martin Dewhurst
Independent Directorless than a yearno datano data
Kent Kester
Independent Directorless than a yearUS$100.00kno data
3.7yrs
Average Tenure
62yo
Average Age

Experienced Board: TTRX's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/19 01:14
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Turn Therapeutics Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.